Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Common Equity (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Common Equity data on record, last reported at $3.0 billion in Q1 2026.

  • On a quarterly basis, Common Equity fell 6.38% to $3.0 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $3.0 billion, a 6.38% decrease, with the full-year FY2025 number at $2.7 billion, down 18.76% from a year prior.
  • Common Equity reached $3.0 billion in Q1 2026 per PCVX's latest filing, up from $2.7 billion in the prior quarter.
  • Over the last five years, Common Equity for PCVX hit a ceiling of $3.4 billion in Q3 2024 and a floor of $359.3 million in Q3 2022.
  • A 5-year average of $1.9 billion and a median of $2.0 billion in 2024 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: surged 291.1% in 2023, then fell 18.76% in 2025.
  • Tracing PCVX's Common Equity over 5 years: stood at $953.6 million in 2022, then skyrocketed by 30.08% to $1.2 billion in 2023, then soared by 166.5% to $3.3 billion in 2024, then dropped by 18.76% to $2.7 billion in 2025, then grew by 11.56% to $3.0 billion in 2026.
  • Business Quant data shows Common Equity for PCVX at $3.0 billion in Q1 2026, $2.7 billion in Q4 2025, and $2.9 billion in Q3 2025.